SynthesisGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2011
Meta-analysis and review on the effect of bevacizumab in diabetic macular edema.
Synthesis in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Comparing the efficacy of glucocorticoids and anti-VEGF in treating diabetic macular edema: systematic review and comprehensive analysis.Frontiers in endocrinology · 2024Pooled it
- The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review.BMJ (Clinical research ed.) · 2012Pooled it
- Combined phacoemulsification surgery and intravitreal triamcinolone injection versus stand-alone surgery in patients with type 2 diabetes: a prospective randomized trial.BMC ophthalmology · 2022Trial
- Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Trial
- Trial
- Current Treatments and Innovations in Diabetic Retinopathy and Diabetic Macular Edema.Pharmaceutics · 2022Review
- [Impact of the SARS-CoV-2 pandemic on diabetic macular edema and prognostic factors].Journal francais d'ophtalmologie · 2021Article
- Update on pharmacotherapy for ocular surface squamous neoplasia.Eye and vision (London, England) · 2019Review
- Optical coherence tomography findings predictive of response to treatment in diabetic macular edema.The Journal of international medical research · 2018Article
- Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice.Clinical ophthalmology (Auckland, N.Z.) · 2018Article
- Clinical biomarkers and molecular basis for optimized treatment of diabetic retinopathy: current status and future prospects.Eye and brain · 2016Review
- The effect of combined treatment of bevacizumab and triamcinolone for diabetic macular edema refractory to previous intravitreal mono-injections.International ophthalmology · 2015Article
- Anti-VEGF Therapy and the Retina: An Update.Journal of ophthalmology · 2015Review
- Efficacy of intravitreal anti-vascular endothelial growth factor or steroid injection in diabetic macular edema according to fluid turbidity in optical coherence tomography.Korean journal of ophthalmology : KJO · 2014Article
- Cost-effectiveness of treatment of diabetic macular edema.Annals of internal medicine · 2014Article
- Intravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis.International journal of ophthalmology · 2013Article
- The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package.ClinicoEconomics and outcomes research : CEOR · 2012Article
- Correlation of macular thickness and posterior hyaloid change following bevacizumab and triamcinolone in diffuse diabetic macular edema in middle-aged patients.International ophthalmology · 2011Article
- Review of therapeutic advances in diabetic retinopathy.Therapeutic advances in endocrinology and metabolism · 2011Article
- Current approaches to the management of diabetic retinopathy and diabetic macular oedema.Drugs · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystematic review and meta-analysis to evaluate the effect of bevacizumab (Avastin) in diabetic macular edema (DME)
methodsPertinent publications were identified through systematic searches of PUBMED and Cochrane Central Register of Controlled Trials. Change in central subfield macular thickness (CSMT) in μm and best-corrected visual acuity (BCVA) in log MAR equivalents were extracted at 6, 12 and 24 weeks, and results compared between groups receiving intravitreal bevacizumab (IVB), a combination of IVB and intravitreal triamcinolone acetonide (IVT), and macular laser photocoagulation or sham control groups.
resultsThe summary mean difference indicated a statistically significant reduction in CSMT at 6 weeks when treated with bevacizumab compared to control. IVB treatment, however, lost significance at 12 weeks and 24 weeks. The summary mean difference in BCVA for IVB group compared to control reached significance only at 6 and 24 weeks. Combination therapy of IVB and IVT did not result in any significant reduction in CSMT or gain in vision compared to treatment with IVB alone at any point in time.
conclusionsCurrent data suggests that IVB is an effective short-term treatment for diabetic macular edema, and that its efficacy wanes after 6 weeks. More trials exploring the therapeutic role of intravitreal bevacizumab in DME need to be conducted to define the role of bevacizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.